Froome: Impossible to say if Wiggins operated in a grey area

Chris Froome has told Cyclingnews that it "is impossible to say if Bradley Wiggins was operating in a grey area" after the revelations surrounding Wiggins' use of the powerful corticosteroid triamcinolone acetonide before the 2011 and 2012 Tours de France, and the 2013 Giro d'Italia. Wiggins won the Tour in 2012, becoming the first British rider to do so. According to the rider, he was prescribed the substance to treat allergies, and the UCI signed off on his TUE requests. No rules were broken, but Team Sky and Wiggins have faced questions over why such a powerful drug was needed and the timing of the administration.

Daniel Benson

Daniel Benson was the Editor in Chief at Cyclingnews.com between 2008 and 2022. Based in the UK, he joined the Cyclingnews team in 2008 as the site's first UK-based Managing Editor. In that time, he reported on over a dozen editions of the Tour de France, several World Championships, the Tour Down Under, Spring Classics, and the London 2012 Olympic Games. With the help of the excellent editorial team, he ran the coverage on Cyclingnews and has interviewed leading figures in the sport including UCI Presidents and Tour de France winners.